SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
NEJM publishes our Phase 2 results for the potential treatment of APOL1-mediated kidney disease (AMKD)
FDA clearance of Investigational New Drug (IND) application for our investigational encapsulated cell therapy for the potential treatment of type 1 diabetes
Vertex announces fourth quarter and full year 2022 financial results
FDA clears Vertex’s Investigational New Drug (IND) application for our mRNA therapy for cystic fibrosis
Vertex to present at the American Society of Hematology (ASH) Annual Meeting
Working at Vertex
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.
Featured Stories
Learn about one of our innovative approaches, cell encapsulation. This is just one of the tools in our drug discovery toolbox that has the potential to treat serious diseases.
Drug discovery is a team sport at Vertex Pharmaceuticals. In recognition of British Science Week, hear from Site Head David Price and scientists in Oxford, U.K., about the power of connections in science.
Vice President of Clinical Development Dr. Ogo Egbuna shares why it’s important to raise awareness about APOL1-mediated kidney disease (AMKD).
Learn about one of our innovative approaches, cell encapsulation. This is just one of the tools in our drug discovery toolbox that has the potential to treat serious diseases.
Drug discovery is a team sport at Vertex Pharmaceuticals. In recognition of British Science Week, hear from Site Head David Price and scientists in Oxford, U.K., about the power of connections in science.
Vice President of Clinical Development Dr. Ogo Egbuna shares why it’s important to raise awareness about APOL1-mediated kidney disease (AMKD).
